SAN FRANCISCO — Syapse, among the highest profile companies in a wave of startups seeking to mine patient data stored in electronic medical records and other portals, last week laid off 18 of its San Francisco-based employees — a move the company attributes to a shift in focus toward data analytics and insights and away from its software business.
The layoffs — which primarily affected Syapse’s engineering division, along with its product management and operations teams — represented about 10% of its workforce. The realignment comes just weeks after the pharma giant Roche prematurely terminated a precision medicine deal with Syapse centered around oncology data.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
I wonder much different this collaboration was versus what Roche already was doing with Flatiron (which they acquired). There seems to be a number of other startups like Picnic Health and Datavant trying to work with life science companies on RWD. I am interested to see what comes out of these collaborations.